Dr. Harshman on Earlier Use of Immunotherapy in RCC

Lauren C. Harshman, MD
Published: Friday, May 18, 2018



Lauren C. Harshman, MD, assistant professor of medicine, Harvard Medical School, senior physician, Dana-Farber Cancer Institute, discusses moving immunotherapy earlier in the line of therapy for patients with renal cell carcinoma (RCC).

Harshman says that the next step in the treatment of patients with RCC is moving immunotherapy into earlier lines of treatment. Investigators are currently testing checkpoint inhibitors such as atezolizumab (Tecentriq) and pembrolizumab (Keytruda). In April 2018, the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) was approved by the FDA as a frontline treatment for intermediate- and poor-risk patients with advanced RCC.

The PROSPER study is looking at adjuvant therapy in a novel way, Harshman says. This trial is giving a few doses of PD-1 priming blockade to activate the immune system. Following this, 9 months of adjuvant nivolumab is given to sustain the immune system and work against micrometastatic disease. Harshman explains that when a significant amount of androgen is in place, a T-cell effector army can be built to take out the tumor.
SELECTED
LANGUAGE


Lauren C. Harshman, MD, assistant professor of medicine, Harvard Medical School, senior physician, Dana-Farber Cancer Institute, discusses moving immunotherapy earlier in the line of therapy for patients with renal cell carcinoma (RCC).

Harshman says that the next step in the treatment of patients with RCC is moving immunotherapy into earlier lines of treatment. Investigators are currently testing checkpoint inhibitors such as atezolizumab (Tecentriq) and pembrolizumab (Keytruda). In April 2018, the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) was approved by the FDA as a frontline treatment for intermediate- and poor-risk patients with advanced RCC.

The PROSPER study is looking at adjuvant therapy in a novel way, Harshman says. This trial is giving a few doses of PD-1 priming blockade to activate the immune system. Following this, 9 months of adjuvant nivolumab is given to sustain the immune system and work against micrometastatic disease. Harshman explains that when a significant amount of androgen is in place, a T-cell effector army can be built to take out the tumor.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x